Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study to evaluate activity and toxicity of Gemcitabine in Combination with Pemetrexed long term infusion in the Treatment of pretreated Metastatic Colorectal Cancer Patients [Studio di fase II per valutare l'attivita e la tossicita del trattamento con Gemcitabina in combinazione con Pemetrexed in infusione continua nei pazienti pretrattati affetti da carcinoma del colon-retto metastatico]

Trial Profile

A Phase II Study to evaluate activity and toxicity of Gemcitabine in Combination with Pemetrexed long term infusion in the Treatment of pretreated Metastatic Colorectal Cancer Patients [Studio di fase II per valutare l'attivita e la tossicita del trattamento con Gemcitabina in combinazione con Pemetrexed in infusione continua nei pazienti pretrattati affetti da carcinoma del colon-retto metastatico]

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 May 2018

At a glance

  • Drugs Gemcitabine; Pemetrexed
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2018 Status changed from recruiting to discontinued, due to toxicity as per results published in the Oncologist.
    • 31 Jul 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01909830).
    • 17 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top